• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

印度中部住院患者分离出的革兰氏阴性杆菌对美罗培南及其他抗菌药物的体外敏感性

In vitro susceptibility to meropenem and other antimicrobial agents among gram-negative bacilli isolated from hospitalized patients in central India.

作者信息

Chitnis S, Chitnis V, Hemvani N, Chitnis D S

机构信息

Department of Microbiology and Immunology, Choithram Hospital and Research Centre, Indore, India.

出版信息

Chemotherapy. 2006;52(1):43-5. doi: 10.1159/000090243. Epub 2005 Dec 9.

DOI:10.1159/000090243
PMID:16340199
Abstract

BACKGROUND

Growing multiple drug resistance among gram-negative bacilli among hospitalized patients is a serious therapeutic problem, and the aim of the study was to assess the situation in our hospital.

METHODS

Antimicrobial susceptibility testing with the disk method was carried out on 1,533 isolates of gram-negative bacilli from urine, pus, body fluid and blood from hospitalized patients.

RESULTS

Seventeen percent of isolates were susceptible only to meropenem and either to piperacillin + tazobactam, to cefoperazone + sulbactam or to both. Eleven percent of isolates were susceptible only to meropenem and 6% were resistant to all antimicrobial agents including meropenem.

CONCLUSION

Growing multiple drug resistance among gram-negative bacilli in hospital practice demands a rigid antibiotic policy and strict infection control measures.

摘要

背景

住院患者中革兰氏阴性杆菌多重耐药性不断增加是一个严重的治疗问题,本研究旨在评估我院的情况。

方法

采用纸片法对1533株来自住院患者尿液、脓液、体液和血液的革兰氏阴性杆菌进行药敏试验。

结果

17%的分离株仅对美罗培南敏感,且对哌拉西林+他唑巴坦、头孢哌酮+舒巴坦其中之一或两者均敏感。11%的分离株仅对美罗培南敏感,6%的分离株对包括美罗培南在内的所有抗菌药物耐药。

结论

医院实际工作中革兰氏阴性杆菌多重耐药性不断增加,需要严格的抗生素政策和严格的感染控制措施。

相似文献

1
In vitro susceptibility to meropenem and other antimicrobial agents among gram-negative bacilli isolated from hospitalized patients in central India.印度中部住院患者分离出的革兰氏阴性杆菌对美罗培南及其他抗菌药物的体外敏感性
Chemotherapy. 2006;52(1):43-5. doi: 10.1159/000090243. Epub 2005 Dec 9.
2
Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA).来自美罗培南年度药敏试验信息收集项目(美国)的重症监护病房和普通病房革兰氏阴性菌分离株的抗菌药敏模式比较。
Diagn Microbiol Infect Dis. 2006 Sep;56(1):57-62. doi: 10.1016/j.diagmicrobio.2005.12.009. Epub 2006 May 2.
3
Antimicrobial resistance among clinical isolates from the Chinese Meropenem Surveillance Study (CMSS), 2003-2008.2003-2008 年中国美罗培南监测研究(CMSS)中临床分离株的抗菌药物耐药性。
Int J Antimicrob Agents. 2010 Mar;35(3):227-34. doi: 10.1016/j.ijantimicag.2009.11.010. Epub 2010 Jan 4.
4
[Changes of antimicrobial resistance among nonfermenting gram-negative bacilli isolated from intensive care units from 1994 to 2001 in China].[1994年至2001年中国重症监护病房分离的非发酵革兰阴性杆菌的耐药性变化]
Zhonghua Yi Xue Za Zhi. 2003 Mar 10;83(5):385-90.
5
Current status of drug resistance among gram-negative bacilli isolated from admitted cases in a tertiary care centre.三级医疗中心收治病例中分离出的革兰氏阴性杆菌的耐药现状。
J Assoc Physicians India. 2003 Jan;51:28-32.
6
Trends in antimicrobial susceptibilities among bacterial pathogens isolated from patients hospitalized in European medical centers: 6-year report of the MYSTIC Surveillance Study (1997-2002).欧洲医疗中心住院患者分离出的细菌病原体抗菌药物敏感性趋势:MYSTIC监测研究6年报告(1997 - 2002年)
Diagn Microbiol Infect Dis. 2005 Apr;51(4):281-9. doi: 10.1016/j.diagmicrobio.2004.11.013.
7
['In vitro' activity of different antimicrobial agents on Gram-negative nonfermentative bacilli, excluding Pseudomonas aeruginosa and Acinetobacter spp].不同抗菌药物对革兰氏阴性非发酵杆菌(不包括铜绿假单胞菌和不动杆菌属)的“体外”活性
Rev Argent Microbiol. 2005 Jan-Mar;37(1):34-45.
8
[The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].[使用亚胺培南、美罗培南、头孢哌酮-舒巴坦和哌拉西林-他唑巴坦治疗医院获得性革兰阴性菌感染的蒙特卡洛模拟可靠性研究]
Zhonghua Nei Ke Za Zhi. 2017 Aug 1;56(8):595-600. doi: 10.3760/cma.j.issn.0578-1426.2017.08.008.
9
Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).美罗培南及对照广谱抗菌药物的当代活性:来自美国部分的MYSTIC项目报告(2005年)
Diagn Microbiol Infect Dis. 2007 Feb;57(2):207-15. doi: 10.1016/j.diagmicrobio.2006.07.009. Epub 2006 Sep 1.
10
Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance.美罗培南在美国医疗中心的比较活性(2007年):启动MYSTIC计划监测的第二个十年
Diagn Microbiol Infect Dis. 2008 Jun;61(2):203-13. doi: 10.1016/j.diagmicrobio.2008.01.017. Epub 2008 Mar 10.